公开(公告)号：US11690873B2

公开(公告)日：2023-07-04

申请号：US16498276

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Cecile Schiffer-Mannioui ,  Philippe Duchateau ,  Anne-Sophie Gautron

IPC: C07K14/705 ,  C07K19/00 ,  A61P35/00 ,  A61K39/395 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  A61P35/02 ,  A61K31/365

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20210059142A1

公开(公告)日：2021-03-04

申请号：US17098210

申请日：2020-11-13

Applicant: CELLECTIS SA ,  MEDICAGO INC.

Inventor： Luc Mathis ,  Daniel F. Voytas ,  Jin Li ,  Feng Zhang ,  Thomas Stoddard ,  Marc-Andre D'Aoust

IPC: A01H1/06 ,  C12N15/82 ,  C12N15/01 ,  C12N9/22 ,  C12P21/00

Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.

公开(公告)号：US20240189354A1

公开(公告)日：2024-06-13

申请号：US18393322

申请日：2023-12-21

Applicant: CELLECTIS SA

Inventor： Julianne SMITH ,  Phillippe DUCHATEAU ,  Murielle DERRIEN

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20210161954A1

公开(公告)日：2021-06-03

申请号：US16498899

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Philippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/02 ,  A61K31/365 ,  C07K14/705 ,  C07K14/725

Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20150272076A1

公开(公告)日：2015-10-01

申请号：US14439420

申请日：2013-10-31

Applicant: CELLECTIS SA ,  MEDICAGO INC.

Inventor： Luc Mathis ,  Daniel F. Voytas ,  Jin Li ,  Feng Zhang ,  Thomas Stoddard ,  Marc-Andre D'Aoust

IPC: A01H5/12 ,  A01H1/06 ,  C12P21/00

CPC classification number: A01H5/12 ,  A01H1/06 ,  C12N9/22 ,  C12N15/01 ,  C12N15/8218 ,  C12N15/8257 ,  C12N15/8258 ,  C12P21/00 ,  C12P21/005

Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.

Abstract translation: 提供材料和方法用于制造适合于产生适于施用于人和动物的治疗性多肽的植物（例如烟草属），特别是通过在编码木糖基转移酶和岩藻糖基转移酶的基因中产生TAL效应子内切核酸酶诱导的突变。

公开(公告)号：US12133867B2

公开(公告)日：2024-11-05

申请号：US18393322

申请日：2023-12-21

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Phillippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20250026808A1

公开(公告)日：2025-01-23

申请号：US18898069

申请日：2024-09-26

Applicant: CELLECTIS SA

Inventor： Julianne SMITH ,  Phillippe DUCHATEAU ,  Murielle DERRIEN

IPC: C07K14/705 ,  A61K31/365 ,  A61K39/00 ,  A61K39/395 ,  A61P35/02 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20230416786A1

公开(公告)日：2023-12-28

申请号：US18253977

申请日：2021-11-30

Applicant: CELLECTIS SA

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Ming YANG

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46 ,  C12N2750/14143

Abstract: The invention provides aminoquinoline compounds as powerful enhancers of genetic recombination in living cells, especially to perform site-directed gene integration of exogenous DNA template by homologous recombination. In particular, disclosed are methods by which cells are treated with chloroquine and/or hydroxychloroquine prior to, or concomitantly with, the introduction of exogenous DNA templates, and optionally in presence of rare-cutting endonucleases, to obtain higher rates of gene integration or correction.

公开(公告)号：US20160304834A1

公开(公告)日：2016-10-20

申请号：US14648336

申请日：2013-11-28

Applicant: CELLECTIS SA

Inventor： Barbara Küppers-Munther ,  Josefina Edsbagge

IPC: C12N5/074

CPC classification number: C12N5/0607 ,  C12N5/0606 ,  C12N5/067 ,  C12N2501/06 ,  C12N2501/16 ,  C12N2501/70 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/03 ,  C12N2506/45

Abstract: The present invention relates to the directed differentiation of mammalian pluripotent stem cells, especially human pluripotent stem (hPS) cells, into endodermal cells. In particular, the present invention relates to the treatment of mammalian pluripotent stem cells, especially hPS cells, with a DNA demethylating agent while undergoing differentiation into endodermal. The inventors have, as disclosed herein, found that exposing differentiating mammalian pluripotent stem cells, especially hPS cells, to a DNA demethylating agent leads to an improved morphology and improved yield of endodermal cells. The treatment with a DNA de-methylating agent also leads to a significant down-regulation of expression of the stem cell marker Oct4 and to an improved expression of endoderm specific markers, notably sox17, cxcr4 and hhex.

Abstract translation: 本发明涉及哺乳动物多能干细胞（特别是人多能干细胞（hPS）细胞）到内胚层细胞中的定向分化。 特别地，本发明涉及在经历分化为内胚层的情况下用脱甲基化剂处理哺乳动物多能干细胞，特别是hPS细胞。 如本文所公开的，发明人发现将分化的哺乳动物多能干细胞，特别是hPS细胞暴露于脱甲基化剂导致内胚层细胞的形态改善和提高的产量。 用DNA去甲基化剂的治疗也导致干细胞标记Oct4的表达的显着下调，并改善了内胚层特异性标志物，特别是sox17，cxcr4和hhex的表达。

公开(公告)号：US20250002945A1

公开(公告)日：2025-01-02

申请号：US18712640

申请日：2022-11-23

Applicant: CELLECTIS SA

Inventor： Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Alex BOYNE ,  Selena KAZANCIOGLU

IPC: C12N15/90 ,  C07K14/195 ,  C12N9/22

Abstract: The present invention relates to the design of improved TALE protein fusions useful as sequence-specific genomic reagents, such as TALE-nucleases and TALE base editors, displaying higher on-target/off-target activity ratios. Its goal is to produce safer reagents to genetically modify the genomes of different types of cells, especially mammalian cells, in particular for their use in gene therapy.